Education
About Us
Working with TipRanks
Follow Us
Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
CYCN Stock Chart & Stats
$1.37
$0.00(0.00%)
At close: 4:00 PM EST
$1.37
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.16 - $6.25
Previous CloseN/A
Volume28.13K
Average Volume (3M)162.78K
Market Cap
$5.69M
Enterprise Value-$29.08K
Total Cash (Recent Filing)$4.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding3,925,314
10 Day Avg. Volume35,401
30 Day Avg. Volume162,776
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.92
Price to Sales (P/S)4.05
P/FCF Ratio-1.87
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.01
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-33.4
Revenue Forecast (FY)$2.04M
Cyclerion Therapeutics News
CYCN FAQ
What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.16 and its highest was $6.25 in the past 12 months.
What is Cyclerion Therapeutics,Inc.’s market cap?
Cyclerion Therapeutics,Inc.’s market cap is $5.69M.
When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
Cyclerion Therapeutics,Inc. released its earnings results on Feb 22, 2024. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.685.
Is Cyclerion Therapeutics,Inc. overvalued?
According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued.
Does Cyclerion Therapeutics,Inc. pay dividends?
Cyclerion Therapeutics,Inc. does not currently pay dividends.
What is Cyclerion Therapeutics,Inc.’s EPS estimate?
Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclerion Therapeutics,Inc. have?
Cyclerion Therapeutics,Inc. has 3,925,314 shares outstanding.
What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
Cyclerion Therapeutics,Inc. reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.42%.
Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
Currently, no hedge funds are holding shares in CYCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cyclerion Therapeutics,Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Technical Analysis
Ownership Overview
15.03% Insiders
0.87% Mutual Funds
4.07% Other Institutional Investors
79.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---